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Introduction
Chronic Lymphocytic Leukemia
(CLL) is a malignancy of CD5+
B cells that primarily occurs in
the blood and bone marrow.
It’s one of the most common
blood cancers in Western
countries and about 10% of
patients diagnosed with CLL
develop into Richter Syndrome
(RS), an extremely aggressive
transformation into lymphoma.
Ultra-conserved
regions
(UCRs) are genomic regions
that are perfectly (100%)
conserved in between humans,
mice and rats. Some of the
UCRs get transcribed into long
noncoding RNAs often called
as Transcribed Ultraconserved
regions. Perfect conservation
of T-UCRs makes them
interesting and aberrations in
such
regions
has
been
correlated
to
cancer
susceptibility.
TRUC-16
is
found to be overexpressed in
aggressive CLL and Richter
patients. Around 4% of patients
exhibit G324A mutation in this
region. Direct interaction of
TRUC-16 to p16INK4A leads to
lower levels of p16INK4A and
overexpressed conditions of
TRUC-16. P16INK4A, a tumor
suppressor, is found to be
silenced in 30% of Richter
Transformation cases.

Hypothesis:
We hypothesize that forced
overexpression of this ncRNA
along with G324A mutation in
B cells leads to aggressive
transformation into RS-like
phenotype in C57BL6 mice.
Such
aggressive
transformation
potentially
leads to migration of naïve B
cells from peripheral system
into spleen and lymph nodes
that eventually drives the
transformation into lymphoma.

Results

Methods
In order to investigate the disease, we phenotyped CRISPR-Knockin mice,
generated in Dr. Calin’s lab. These mice have B-Cell specific overexpressed
TRUC-16 given that uc.206 is under control of Vh promoter and IgH-Eµ
enhancer which target expression to B-cell compartment..
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Figure 1: CRISPR Cas9 Knock-In strategy. Cas9 with donor plasmids were injected into
zygotes of mice. Backcrossing was performed to obtain pure breeds which were subjected
to further genotyping.

Transgenic mice cohorts (TgMut) were subjected to genotypic screening.
Genotyping is a very important step in our experiments. This lets us tell apart
the mice from Heterozygous, homozygous insert and wildtype littermates.
Genotyping is done by snipping a small part of the mouse’s ear/tail which is
then lysed in the lab until its homogeneous. Afterwards, a PCR is performed
with the go taq green protocol and then loaded into a 2% gel to assess the
different base pairs in each well.
Primer 1
L HE
1000bp

Primer 2
HI

HI

WT

L HE

HI

HI

WT
1000bp

100bp

Figure 2: Genotyping of B-cell specific
overexpress TRUC-16 mice subjected to two
sets of nested primers. L: Ladder; HE:
Heterozygous; HI: Homozygous Insert; WT:
Wildtype.

Furthermore, we performed flow cytometry to assess lymphocytes in the
peripheral blood. Flow cytometry analysis was performed using two panels
comprising of CLL markers (CD5, B220, CD19, IgK and Igl) and Richter panel
including CD23, CD20, and Ki-67. Retro-orbital bleedings were performed on
mice to collect peripheral blood that was further subjected to surface and
intracellular staining. Data was acquired using BD LSR Fortessa and further
analyzed using FlowJo software.

Figure 4. A depicts lower CD20+ CD19+ immature B cells in
the peripheral blood of TgMut++ mice compared to wildtype
littermates. B shows lower proliferating immature B cells in
TgMut++ mice compared to wildtype littermates. C and D
shows lower population of immature B cells in the peripheral
blood of TgMut++ mice compared to wildtype littermates
validating the findings in A and B. TgMut depicts mice having
overexpression of TRUC-16 along with G324A mutation

Conclusion

Our results depict lower population of immature B
cells in the peripheral blood of TgMut++ mice
compared to the wildtype littermates. Potentially,
these immature B cells are migrating to the spleen
and lymph node during the initiation of transformation
that needs to further investigated. Preliminary data
from the lab show that high grade B cell lymphoma in
adult TgMut++ mice (data not shown).

Future Directions
Flow cytometry analysis using CLL and RS Panel on
single suspension cells from spleen and lymph nodes.
Further, to characterize the B cell subtype, we would
design a new panel utilizing CD80, CD27, CD138 and
other B cell markers to better understand the B cell
population in the immune compartment of these
TRUC-16 overexpressing mice.
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Figure 3. Process of Flow Cytometry. Blood collection from mice through retro-orbital bleeding
followed by immunophenotyping through multiparameter flow cytometry analysis.
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